Backed by the combined expertise of three USC schools, scientists are developing a new drug aimed at a previously unexplored ...

On 23 September 2025 the TGA made the decision to approve the registration of the lecanemab (LEQEMBI).What is LEQEMBI ...

LEQEMBI is a monoclonal antibody that is administered in a specialised centre via a one-hour intravenous infusion every two weeks and targets the underlying pathology of Alzheimer's disease. 1,2 ...

Eisai and Biogen (BIIB) announced that the Therapeutic Goods Administration, TGA,of Australia has approved the humanized anti ...

The Therapeutic Goods Administration approves the drug Lecanemab, which can slow down cognitive decline in the early stages ...

A groundbreaking study from the Mayo Clinic reveals how chronic insomnia can accelerate cognitive decline and increase the ...

Last week, HC Wainwright hosted Voyager Therapeutics, Inc.’s (NASDAQ:VYGR) management during HCW's Annual Global Investment ...

A new treatment for Alzheimer’s disease has been registered with the TGA to help patients with early to mild conditions.

Participants were classed as having chronic insomnia if their medical records contained at least two insomnia diagnoses a ...